Clinical trial · Interventional
STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
A Biomarker Study of STA9090 in Castration-Resistant Prostate Cancer (CRPC) With Assessment of Androgen Receptor Pathway Signaling
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Loss of funding.
Summary
Brief summary (as posted)
In this research study, the investigators are looking to determine the safety and efficacy of an investigational drug, STA9090 alone and in combination with dutasteride for the treatment of castrate resistant prostate cancer. STA9090 may cause the growth of cancer to slow down or shrink by targeting proteins required for the cancer to grow. The investigators are also looking to determine whether the use of dutasteride to lower male hormone levels will enhance the effect of STA9090 in the treatment of castrate resistant prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of the Prostate | Prostate Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| STA9090 | Drug | Ganetespib | ALIAS |
| STA9090 with Dutasteride | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- STA9090 with Dutasteride
- description
- STA9090 with Dutasteride
- interventionNames
- Drug: STA9090 with Dutasteride
- type
- EXPERIMENTAL
- label
- STA9090
- description
- STA9090
- interventionNames
- Drug: STA9090
Primary outcomes (1)
- measure
- To assess AR transcriptional activity based on expression of a series of AR regulated genes, in baseline and on therapy tumor biopsies in CRPC patients treated with STA- 9090 +/-dutasteride.
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adenocarcinoma of the prostate * Progressive castration resistant disease * Metastatic disease * Normal organ and marrow function Exclusion Criteria: * History of current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass * Current treatment with the following antiarrhythmic drugs: flecainide, moricizine or propafenone * New York Heart Association class II/III/IV congestive heart failure * Current or prior radiation therapy to the left hemithorax * Treatment with chronic immunosuppressants * Uncontrolled intercurrent illness * Poor venous access for study drug administration * Venous thromboembolism in the past 6 months
References
Publications (0)
Data not yet available